Activated Pneumococcal Polysaccharide Conjugates for Serotypes 10A, 22F, 33F
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pneumococcal vaccines do not provide adequate protection against Streptococcus pneumoniae serotypes 10A, 22F, or 33F, particularly in children under 2 years old.
Innovation Solution
Development of an immunogenic conjugate comprising activated Streptococcus pneumoniae serotype 10A, 22F, or 33F polysaccharides covalently linked to a carrier protein, using a process involving oxidation and quenching followed by conjugation with a reducing agent.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current pneumococcal vaccines are used, then protection against common serotypes is achieved, but protection against serotypes 10A, 22F, or 33F is insufficient
Solution Approach 1:
The vaccine composition is segmented to include specific polysaccharide components from serotypes 10A, 22F, and 33F in addition to the standard 23-valent polysaccharides. This segmentation allows the vaccine to provide targeted protection against previously uncovered serotypes while maintaining protection against common serotypes, thereby resolving the contradiction between reliability and adaptability.
Solution Approach 2:
The invention creates a composite vaccine formulation by combining the 23-valent polysaccharide mixture with purified polysaccharides from serotypes 10A, 22F, and 33F. This composite approach enables the vaccine to simultaneously provide broad-spectrum protection against common serotypes and specific protection against the previously uncovered serotypes, resolving the technical contradiction.
2Reliability
If polysaccharides are oxidized to create activated polysaccharides for conjugation, then immunogenicity is improved, but molecular weight and structural integrity may be compromised
Solution Approach 1:
The oxidation process parameters are carefully controlled to achieve the desired degree of activation without excessive degradation. By optimizing parameters such as oxidizing agent concentration, reaction time, and temperature, the process achieves sufficient immunogenicity enhancement while maintaining acceptable molecular weight and structural integrity of the polysaccharides.
Solution Approach 2:
The oxidation is performed to a partial extent rather than complete oxidation, achieving sufficient activation for improved immunogenicity while avoiding the severe structural degradation that would result from excessive oxidation. This partial action approach balances the competing requirements of immunogenicity enhancement and structural preservation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The immunogenic conjugate induces an immune response against serotypes 10A, 22F, and 33F, providing effective protection against Streptococcus pneumoniae infections.
Implementation Method 1
reacting an isolated serotype 10A, 22F or 33F capsular polysaccharide with an oxidizing agent
Implementation Method 2
quenching the oxidation reaction by addition of a quenching agent
Implementation Method 3
reacting the compounded, activated serotype 10A, 22F or 33F polysaccharide and carrier protein with a reducing agent to form a serotype 10A, 22F or 33F polysaccharide:carrier protein conjugate
Data Source
AI summary
The invention relates to activated Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides and processes for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides covalently linked to a carrier protein, processes for their preparation and immunogenic compositions and vaccines comprising them.